Direct Acting Agents in Hepatitis C Patients

Evaluation of Efficacy and Safety of Direct Acting Agents in Hepatitis C Patients

This study is a retrospective study conducted at 36 sites. Planned target patient number is 1000.

Approximately 36 centers will be included in Turkey. Centers will be selected from clinics of infection and clinical microbiology. The inclusion of 1000 patients was targeted. All data will be retrospectively collected from the medical records of the patients. Patient visit is not necessary.

Inclusion Criteria:

• Patients who used direct acting agents for Hepatitis C

Exclusion Criteria:

• Patients younger then 18 years